[Ip-health] CPATH statement on 301 reports and Guatemala

[Ellen Shaffer]

This is a multi-part message in MIME format.
--
--
[ Picked text/plain from multipart/alternative ]
CPATH has submitted a statement to the U.S. Trade Representative on the
misuse of 301 Reports to pressure and penalize Guatemala for exercising
legal measures to provide affordable medicines.  We also submitted a
copy of our journal article on that subject.  Please see the statement
and article at the links below:


2010 Special 301 Review: Identification of Countries Under Section 182
of The Trade Act of 1974

*Submission of Center for Policy Analysis On Trade And Health (CPATH) ?
Comments on Special 301 Regarding Access to Medicines *

http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480aa7c77



*A Trade Agreement'?s Impact On Access To Generic Drugs, ? Shaffer and
Brenner, */_Health Affairs_/, 28, no. 5 (2009): w957-w968

CPATH?s report demonstrates how intellectual property rules in the U.S.
- Central America Free Trade Agreement (CAFTA) keeps lower-priced
generic versions of life-saving drugs off the shelves and out of the
hands of some of the poorest people in our hemisphere.

http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480aa7cd7


These remarks expand on our contribution to the  excellent joint
statement presented by Global Health Organizations, and distributed to
these lists earlier by Sean Flynn.

--
Ellen R. Shaffer, PhD MPH
Co-Director, Center for Policy Analysis
San Francisco Presidio
P.O. Box 29586
San Francisco, CA 94129-0586
phone: 415-922-6204
mobile: 415-680-4603
fax: 415-885-4091
www.centerforpolicyanalysis.org


--
[ Federal Register postings.doc of type application/msword deleted ]
--
[ ershaffer.vcf of type text/x-vcard deleted ]